B+
Bull case
20%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
CRDF
Cardiff OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+42.1
Score
AI commentary
News tone is modestly constructive from the CRDF-004 data and FDA-aligned Phase 3 path, but financing dilution and unresolved clinical, regulatory, and licensing risks offset that signal. The scheduled T+3 earnings follow-up remains unverified; revenue/EPS surprise, guidance, analyst revisions, transcript commentary, and attributable post-print market reaction are unavailable. Social coverage is absent, and the loose peer set limits confidence.
RankAlpha Sentiment Codex - 2026-08-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 earnings release and guidance checkMedium impact
The scheduled 2026-07-30 T+3 earnings follow-up could not be confirmed: no verified Q2 release, 8-K exhibit, transcript, consensus surprise, guidance revision, analyst target change, or earnings-linked price explanation was available in the packet or bounded primary-source check. The latest verified earnings update reported $46.1 million of cash and investments and runway into Q1 2027 [#SEC-8K-2026-05-14]. This is an evidence gap, not a positive catalyst.
2026-11-02eventPhase 3 design and regulatory-strategy updateHigh impact
Cardiff reported completion of an End-of-Phase 2 FDA meeting, selection of 30 mg onvansertib with FOLFIRI/bevacizumab for Phase 3, and plans to share additional Phase 3 and regulatory details in mid-2026. Subsequent confirmation was not found, reducing confidence [#SEC-8K-2026-05-14].
2026-11-02catalystEquity financing and warrant dilutionHigh impact
The July financing included 8.57 million common shares and accompanying warrants, with additional insider shares and warrants. The common warrants carry future exercise potential, creating dilution and supply overhang near a sub-$1 share price [#SEC-8K-2026-07-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology